Acceptance rate and sociological factors involved in the switch from originator to biosimilar etanercept (SB4)

2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative

Daniel Aletaha, Tuhina Neogi, Alan J. Silman et al. · Arthritis & Rheumatism · 2010 · 9.6K citations · Full text

Medicine, Internal Medicine, Clinical Classification Systems +13

The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal

Martín Rudwaleit, R. Landewé, Désirée van der Heijde et al. · Annals of the Rheumatic Diseases · 2009 · 943 citations

Medicine, Radiology, Diagnostic Radiology +10

Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial

Kristin Kaasen Jørgensen, Inge Christoffer Olsen, Guro Løvik Goll et al. · The Lancet · 2017 · 806 citations

Pharmacy, Internal Medicine, Pharmacotherapy +11

A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry

Bente Glintborg, Inge Juul Sørensen, Anne Gitte Loft et al. · Annals of the Rheumatic Diseases · 2017 · 249 citations

Medicine, Clinical Sciences, Internal Medicine +17

Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases

Jonathan Kay, Monika Schoels, Thomas Dörner et al. · Annals of the Rheumatic Diseases · 2017 · 216 citations

Medicine, Dermatology, Pharmacotherapy +17